Outbreak among drug users caused by a clonal strain of group A streptococcus by Böhlen, LM et al.
Dispatches
175Vol. 6, No. 2, March–April 2000 Emerging Infectious Diseases
In the 1980s, reemergence of severe group A
streptococcus (GAS) infections, especially toxic
shock syndrome, necrotizing fasciitis, and
bacteremia associated with high death rates, was
observed (1,2). Temporal and geographic cluster-
ing of cases with severe GAS infection has been
described (3,4). Outbreaks caused by clonal
strains have been reported in households,
schools, and hospitals (5).
In September 1997, a sudden increase was
observed in needle abscesses due to GAS among
drug users hospitalized in Berne, Switzerland.
Analysis of GAS isolates suggested that the
outbreak was caused by clonal strains. An
outbreak investigation included a case-control
study of potential sources and risk factors for
acquisition of GAS infection among drug users in
Berne. To our knowledge, this is the first report of
an outbreak among drug users of invasive GAS
infections caused by clonal strains.
The Study
Cases of GAS infection were identified
through culture records of the Institute of
Medical Microbiology, University of Berne,
Switzerland. During September to December
1997, all GAS isolates from any site were
prospectively stored and included in the study.
Cases were defined as GAS infection in drug
users from September 22 to November 20, 1997,
due to the outbreak strain, as determined by
pulsed-field gel electrophoresis (PFGE).
During December 15-20, 1997, controls were
randomly chosen from drug users visiting a
government shelter for drug use and needle
exchange in Berne. An exclusion criterion was a
skin infection at an injection site since September.
Drug users with cases, as well as controls,
were interviewed by a standardized question-
naire including age, employment, recent infec-
tions, and drug use habits (Table). Crude odds
ratios and 95% confidence intervals were
calculated with EpiInfo software, version 6.02
(CDC, Atlanta, GA). Categorical data were
compared with Fisher’s exact test or the chi-
square test, and continuous data with Student’s t-
test. To identify independent risk factors, logistic
regression analysis was performed in EGRET
(Seattle, WA).
GAS was isolated on sheep blood agar and
identified by gram staining and the bacitracin
test (6). Throat swabs were obtained at the time
of the interview from the 55 controls. Culture
specimens were taken with moistened (sterile
saline) swabs from spoons (n = 10) and filters
(n = 2) used for drug preparation.
Samples of cocaine confiscated by police
during September 15-28 and October 12-20 were
cultured for GAS. The drug specimens had been
stored for 1 to 6 weeks in a dry place before
culture. For each cocaine specimen, three 0.2-g
samples were dissolved in sterile saline. One
sample was inoculated into tryptic soy broth
(TSB); the other two were filtered through sterile
0.45-m membranes. One filter was placed on a
sheep blood agar plate, and the other was
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We describe an outbreak among drug users of severe soft-tissue infections caused
by a clonal strain of group A streptococcus of M-type 25. Cases (n = 19) in drug users
were defined as infections (mainly needle abscesses) due to the outbreak strain.
Comparison with controls showed that infected drug users bought drugs more often at a
specific place. Drug purchase and use habits may have contributed to this outbreak.
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Table. Sociodemographic and drug use habits of 19 drug users with group A streptococcal infection and 55 healthy controls, Berne,
Switzerland, 1997
Cases n=19   Controls n=55 Odds
Variable   N %    N % Ratio 95% CIa
Age
  Mean (yrs) 30.3 30.7
  Range (yrs) 20-43 21-48
Sex
  Male   9 47.4 3 8   69.1  Ref. 0.76-8.26
  Female 1 0 52.6 1 7   30.9   2.48
Employed
  No 1 2 63.2 3 3   60.0  Ref.
  Yes   6 31.6 1 5   27.3   1.10 0.30-4.00
  Unknown   1   5.3   7   12.7
Daytime shelter
  Home or work   7 36.9 2 0   36.4  Ref.
  Street   8 42.1 2 0   36.4   1.14 0.30-4.40
  Unknown   4 21.1 1 5   27.2
Nighttime shelter
  Home 1 4 73.7 2 9   52.7  Ref.
  Street   3 15.8 1 0   18.2   0.62 0.10-3.06
  Unknown   2 10.5 1 6   29.1
Sharing of paraphernalia
 for drug use
Fil ter
  No   9 47.4 3 4   61.8  Ref.
  Yes   8 42.1 2 1   38.2   1.44 0.42-4.92
  Unknown   2 10.5   0     0.0
Spoon
  No   8 42.1 2 8   50.9  Ref.
  Yes   9 47.4 2 7   49.1   1.08 0.32-3.68
  Unknown   2 10.5   0     0.0
Needle
  No 1 5 78.9 4 9   89.1  Ref.
  Yes   1   5.3   5     9.1   0.65 0.03-6.68
  Unknown   3 15.8   1     1.8
Cocaine heating
  No 1 6 84.2 3 5   63.6
  Yes   0   0.0   6   10.9  p = 0.17
  Unknown   3 15.8 1 4   25.5
Mode of drug use
  Intravenousb 1 7 89.3 5 5 100.0
  Mucosal only   1   5.3   0     0.0
  Unknown   1   5.3   0     0.0
Illegal drug used
  Cocaine   2 10.5   7 127
  Heroin   0   0.0   2     3.6
  Both 1 6 84.2 4 6   83.6
  Unknown   1   5.3   0     0.0
Methadone programc
  No 1 8 94.7 4 0   72.7  Ref.
  Yes   1   5.3 1 5   27.3   0.15 0.01-1.23
No. of drug use(s)
  <1 per day   4 21.1 2 1   38.2  Ref.
  >1 per day 1 3 68.4 2 9   52.7   2.35 0.59-10.04
  Unknown   2 10.5   5     9.1
Cocaine used
  <1 g per day   7 36.8 3 0   54.5  Ref.
  >1 g per day   8 42.1 1 0   18.2   3.43 0.84-14.34
  Unknown   4 21.1 1 5   27.3
Nationality of dealer(s)
  Not A   4 21.1 1 5   27.3  Ref.
  Only A   6 31.6 1 3   23.6   1.73d 0.32-9.59
  Several including A   4 21.1 2 0   36.4
  Unknown 5 26.3 7 1     2.7
Dealer location
  Place X   8 42.1   1     1.8 27.43 2.57-696.75
  Other places   7 36.8 2 4   43.6  Ref. p <0.001
  Not Berne   0   0.0   1     1.8
  Unknown   4 21.1 2 9   52.7
a95% confidence interval
bIncludes combined intravenous and mucosal drug use for one case and seven controls.
cGovernment-approved methadone program.
dComparing “only nationality A” and “not A.”
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Figure. Pulsed-field gel electrophoresis of group A
streptococci causing clinical infection in 19 drug
users, Berne, Switzerland.
M = molecular weight standards. All other lanes represent
PFGE pattern of group A streptococcus isolates from 19
drug users.
  M         M                M               M            M
inoculated into 500 ml TSB. Cultures were
incubated at 37°C. Subcultures from TSB were
placed on sheep blood agar at 12-hour intervals
until the broth became turbid.
PFGE was performed on GAS isolates as
described (7). Briefly, whole genomic DNA was
restricted with SmaI, and fragments were
separated in a CHEF DRIII unit (BioRad,
Glattbrugg, Switzerland) under the following
conditions: 0.5xTRIS-borate-EDTA running
buffer, 6 volts/cm, 14°C, 120°C angle, and a 1.2- to
54-s ramped switch time for 18 hours. Gels were
stained with bromide, and banding patterns
were compared. Only isolates with identical
banding patterns were considered to belong to
the same clone.
The M-type of the outbreak strain was
determined by PCR amplification and sequencing
of a region of the emm gene (3,8). The presence of
the pyrogenic exotoxin A gene was evaluated as
described (3).
PFGE analysis of isolates showed that 19 of
the 21 infections were caused by the same clone
(Figure). Most of these infections (16 of 19) were
needle abscesses at the injection site; two were
complicated by erysipelas and one by osteomyeli-
tis distant from the needle abscess. None of the
patients had streptococcal toxic shock syndrome
(1). Seventeen cases required inpatient treat-
ment, including surgery; all patients recovered.
All patients lived (n = 16) or purchased drugs in
Berne (n = 3).
Cases and controls did not differ by mean age,
current employment status, sharing of parapher-
nalia (e.g., needles, spoons, and filters) for drug
use, and place of shelter (Table).
No GAS could be isolated from the eight
confiscated cocaine samples. Five (9%) of 55
controls were colonized by GAS at the time of the
interview; three of them carried the outbreak
strain. Unfortunately, four of the five colonized
controls refused to disclose the location and
nationality of their drug dealer(s). One admitted
buying drugs in various places, including place X,
and from dealers of several nationalities,
including nationality A. He was colonized by the
outbreak strain.
The outbreak strain was M-type 25, which did
not carry the gene encoding for the pyrogenic
exotoxin A. The strain was susceptible to
penicillin, clindamycin, and erythromycin, as
determined by E-testing.
Conclusions
During the past decade, GAS infections have
attracted increased attention because of their
worldwide reemergence. Molecular typing stud-
ies suggested that this might have been due to the
intercontinental spread of a virulent clone of M-
type 1 (3). Isolates of other M-types have since
been associated with clusters of severe
infections (9). Person-to-person spread by
respiratory droplets from colonized patients or
asymptomatic carriers has been thought to be the
main mode of transmission. Vaginal carriage of
GAS in health-care workers has been associated
with nosocomial spread of GAS (10). Acquisition
of GAS by contaminated food and foodborne GAS
outbreaks has also been described (11).
The epidemic of GAS infections among drug
users described here is to our knowledge the first
report of a clonal epidemic with GAS in this
patient population. GAS is commonly isolated
from soft-tissue infections in intravenous drug
users (12,13). High rates of pharyngeal carriage
with epidemic clones may play a role in this high
frequency of GAS infections, although no
clonality of such GAS isolates was found in two
studies (14,15).
The case-control study showed a strong
association between infection and purchase of
drugs at X, a place commonly used for drug
dealing in Berne. The association with place X
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was strong enough that bias due to the high
refusal rate among controls is unlikely.
Outbreaks of infections with other pathogens
were previously described in drug users (e.g., C.
tetani, C. botulinum, Candida albicans, and
hepatitis A virus) (16-20). These outbreaks could
be due to contamination of the drug or drug
paraphernalia. In our population, sharing
paraphernalia such as needles, spoons, and
filters was reported infrequently and did not
differ between cases and controls. We believe that
this strain of GAS was spread through cocaine or
its containers. Drug dealers and users often hide
cocaine in their mouths during police raids.
Therefore, GAS may be spread to drug users by
contamination of the plastic bags containing the
cocaine or the cocaine itself from persons with
GAS colonization of the mouth and throat. The
strong association of the outbreak with a common
place of drug purchase suggests that one or
several drug dealers there were colonized by the
outbreak strain and spread it by contaminated
drug containers or respiratory droplets. Infected
drug users may also have become colonized by
hiding the drug containers in their mouths.
Alternatively, GAS may have entered the
subcutaneous tissue directly by contaminated
drug or handling paraphernalia with contami-
nated hands. Although we were not able to
culture GAS from cocaine samples, the drug
cannot be ruled out as a potential vehicle of GAS,
since these samples had been stored for some
weeks and GAS may not survive in sufficient
numbers in dry (cocaine) powder.
We obtained a throat culture from only one of
the infected drug users, because they had already
received antibiotics for at least 1-2 days when
they were identified by the microbiologic studies.
The single throat culture showed carriage of the
outbreak strain in the throat as well as at the site
of infection (erysipelas of the leg). Oropharyngeal
carriage of the outbreak strain was also found in
5.4% of our controls; the strain was not found in
randomly selected isolates from nondrug users,
indicating that the outbreak strain was probably
circulating mainly in the drug user population.
Needle abscesses in drug users have been
associated with cocaine use. The local vasocon-
striction induced by cocaine may predispose to
abscess formation (13,21). Cocaine, unlike
heroin, is usually not heated before injection,
since it is thought to lose its activity when heated.
Failure to heat the drug likely increases the risk
of inoculating pathogens. In our study, none of
the 19 cases heated the dissolved cocaine, while
six of the controls did. Some reported that they
started to heat the drug after hearing about the
outbreak.
From the end of the outbreak in November
1997 to May 1998, we observed three sporadic
cases of infection due to the outbreak strain
among drug users, but not the general
population. A retrospective analysis by PFGE of
clinical GAS isolates cultured in our institution
demonstrated that the outbreak strain has been
circulating among drug users in Berne since at
least February 1997. This study also revealed two
previous clonal GAS outbreaks among drug users
in 1993 (unpubl. obs.). These findings suggest
that GAS outbreaks may be observed among drug
users more frequently than previously appreci-
ated and that their propagation may involve
transmission of the outbreak clones by mecha-
nisms related to drug purchase and use.
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